Evaxion Biotech A/s F-1 registration statements

Evaxion A/S files an F-1 registration statement for the resale of 769,000 American Depositary Shares by the European Investment Bank, stemming from a debt settlement.

Evaxion Biotech A/S plans to offer American Depositary Shares (ADSs) and warrants in a best efforts offering.

Evaxion Biotech A/S is conducting a best-efforts offering to raise up to $10.85 million through the sale of American Depositary Shares and warrants to fund its clinical and preclinical programs.

Evaxion Biotech A/S is proposing a public offering of up to 7,530,120 American Depositary Shares (ADSs) and pre-funded warrants to purchase up to 7,530,120 ADSs.

Evaxion Biotech is offering up to 5,252,100 American Depositary Shares and pre-funded warrants to raise capital for its AI-driven vaccine development programs.

Evaxion Biotech A/S has filed an amendment to its registration statement for the resale of up to 19,453,796 ordinary shares represented by 1,945,379 American Depositary Shares (ADSs) by selling shareholders.

Evaxion Biotech is filing an amendment to its registration statement for the resale of up to 19,453,796 ordinary shares represented by 1,945,379 American Depositary Shares (ADSs) by selling shareholders.

Evaxion Biotech is registering for resale up to 19,453,796 ordinary shares represented by 1,945,379 American Depositary Shares (ADSs) by selling shareholders.

Evaxion Biotech A/S is seeking to raise up to $15 million through an offering of American Depositary Shares (ADSs) and warrants.

Evaxion Biotech A/S files an amendment to its Form F-1 registration statement, primarily to include an updated exhibit related to an engagement agreement with H.C. Wainwright & Co., LLC.

Evaxion Biotech A/S plans a public offering of ADSs and warrants to fund its preclinical and clinical pipeline and support ongoing operations.

Evaxion Biotech launches a public offering of ADSs and warrants, aiming to raise $10 million to advance its AI-driven vaccine pipeline.